Providing $250,000 per year over three years, the award will support Dr. Landau’s development of novel technology to study clonal mosaicism in normal tissues. This research will open a critical window into the earliest stages of cancer formation.
The Mark Foundation states that Dr. Landau’s application of “novel single-cell sequencing technologies to study the mechanisms underlying the growth advantage in cancer” will fill a “gap in knowledge” regarding cancer mutations and their growth.
An oncologist and a Core Member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, Dr. Landau’s long-term goal is to develop novel technologies to address cancer evolution as a central obstacle to cure. He received his M.D. from the Sackler School of Medicine at Tel Aviv University and a Ph.D. in Cancer Biology from Paris Diderot University. He completed his residency in Internal Medicine and a fellowship in hematology and medical oncology at Yale University and was a postdoctoral fellow in cancer genomics at the Dana-Farber Cancer Institute and the Broad Institute.